In-Body CAR-T therapy takes aim at Hard-to-Treat blood cancer
NCT ID NCT07586709
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests the safety of a new immunotherapy that creates cancer-fighting cells inside the body for people with relapsed or refractory plasma cell neoplasms, a type of blood cancer. The treatment targets two proteins (BCMA and GPRC5D) on cancer cells. Researchers will monitor side effects like cytokine release syndrome and nerve toxicity in 18 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMA CELL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.